Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”
Cancer · 15.03.2026 · 132 (6)
DOI: 10.1002/cncr.70342 ↗Kurz gefasst
Korrektur in der Zeitschrift Cancer, online erschienen am 13.03.2026.
Abstract (Originalsprache)
Martin TG, Mateos M-V, Yi JH, et al. Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: pooled findings from three clinical cohorts and a retrospective cohort. Cancer. 2026;e70237. doi:10.1002/cncr.70237 This correction is issued to address the following updates: 1. Figure 1C previously contained incorrect patient-at-risk numbers for overall survival (OS); the corrected Figure 1C is shown below. 2. Figure 2B previously contained incorrect patient-at-risk numbers for duration of response (DOR) and progression-free survival (PFS); the corrected Figure 2B is shown below. We apologize for these errors.
Zitieren
APA
(2026). Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”. Cancer, 132(6). https://doi.org/10.1002/cncr.70342
Vancouver
Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”. Cancer. 2026;132(6). doi:10.1002/cncr.70342
BibTeX
@article{euvimed2026,
title = {Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”},
journal = {Cancer},
year = {2026},
volume = {132},
number = {6},
doi = {10.1002/cncr.70342}
}
EUVIMED